ArticleStem cell and regenerative medicine (Wilmington, Del.)2024
Evaluation of Antibodies for Vascular Smooth Muscle Cell Characterization.
Article in Stem cell and regenerative medicine (Wilmington, Del.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An Enriched Primary Culture Reveals Morphological Heterogeneity of Rat Testicular Telocytes.Cells · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Flow cytometry, paired with fluorescent antibodies, is a popular method for characterizing cell phenotypes. Our laboratory is interested in deriving and characterizing vascular smooth muscle cells from embryonic and induced pluripotent stem cells, one of the few stem cell differentiation methods that remain underdeveloped. In our studies, we found that most commercially available antibodies advertised for smooth muscle cell identification using flow-activated cell scanning (FACS) were, in fact, not able to distinguish between positive and negative controls. Attempts to resolve the issues included exploring a range of incubation times, blocking reagents, staining kits, and titrating dilutions against both positive and negative control cells. In the end, we found that only the smooth muscle myosin heavy chain (SMMHC) antibody at a narrow titrating dilution range could distinctly bind to its intended epitope. Moreover, without more adequate and specific antibodies for labelling smooth muscle cells, we were not able to continue with our studies on smooth muscle cell fate.
Indexed as
Identifiers
39512442PMC11542737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.